Regenerative Med Firm Cardio3 Buys Novel Heart Access Platform
This article was originally published in The Gray Sheet
Executive Summary
Cardiac-focus regenerative medicine firm Cardio3 BioSciences is weighing alternative commercialization models for CorQuest Medical heart access devices it is acquiring. The devices also could eventually play a role in delivering Cardio3's cell therapies.